Stock 002393 TIANJIN LISHENG PHARMACEUTICAL CO.,LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Tianjin Lisheng Pharmaceutical Co.,Ltd.

Equities

002393

CNE100000NJ9

Pharmaceuticals

End-of-day quote Shenzhen S.E.
Other stock markets
 06:00:00 2024-07-02 pm EDT 		5-day change 1st Jan Change
15.75 CNY -1.93% Intraday chart for Tianjin Lisheng Pharmaceutical Co.,Ltd. -0.94% -15.52%
Jun. 28 Grand Pharmaceutical Co., Ltd. entered into the Equity Transfer Agreement to acquire remaining 24.65% stake in Tianjin Tanabe Seiyaku Co, Ltd. from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 120 million. CI
Jun. 17 Lishen Releases 5MWh AC and DC Integrated Energy Storage System and New Generation of Wall-Mounted Residential Energy Storage Product CI
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In

Latest news about Tianjin Lisheng Pharmaceutical Co.,Ltd.

Grand Pharmaceutical Co., Ltd. entered into the Equity Transfer Agreement to acquire remaining 24.65% stake in Tianjin Tanabe Seiyaku Co, Ltd. from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 120 million. CI
Lishen Releases 5MWh AC and DC Integrated Energy Storage System and New Generation of Wall-Mounted Residential Energy Storage Product CI
Lisheng Pharmaceutical Avails of 92-Day Structured Deposit Product MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces Final Cash Dividend Plan on A Shares for the Year 2023, Payable on 28 May 2024 CI
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Tianjin Lisheng Pharmaceutical Co.,Ltd. Proposes Cash Dividend for the Year 2023 CI
Tianjin Lisheng Pharmaceutical's 2023 Profit Surges on Gains from Asset Disposals; Shares Jump 4% MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. acquired 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. CI
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Lisheng Pharmaceutical Buys 65% Stake in Qingchun Kangyuan Pharmaceutical for 137 Million Yuan; Shares Up 3% MT
Tianjin Arm Lisheng Pharmaceutical To Buy Chinese Medicine Firm Jiangxi Qingchun Kangyuan MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. agreed to acquire 65% stake in Jiangxi Qingchun Kangyuan Pharmaceutical Co., Ltd. from Jiangxi Qingchun Kangyuan Group Co., Ltd. and Jiangxi Qingchun Kangyuan Chinese Medicine Co., Ltd. for approximately CNY 140 million. CI
Tianjin Lisheng Pharma Setting Up Venture Capital Fund MT
Lisheng Pharmaceutical and Lisheng Investment Enter into the Partnership Agreement with Bozheng Capital, Tianjin Jinjia and Tianjin Handeway CI
Tianjin Development to Vote Dec. 5 on Lisheng Pharma's Sale of Tianjin Pharmaceutical Finance Stake MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited agreed to acquire additional 15% stake in Tianjin Pharmaceutical Group Finance Co., Ltd from Tianjin Lisheng Pharmaceutical Co.,Ltd. for CNY 87.8 million. CI
Lisheng Pharmaceutical's H1 Attributable Profit Jumps MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Lisheng Pharmaceutical Subscribes for 20 Million Yuan Wealth Management Product MT
Lisheng Pharma to Receive 247.9 Million Yuan for Relocation MT
Lisheng Pharmaceutical Eyes 247.9 Million Yuan from Potential Land Resumption Deal MT
Tianjin Lisheng Pharmaceutical Co.,Ltd. Announces 2022 Final Profit Distribution Plan to Be Implemented (A Shares), Payment Date Is 30 June 2023 CI
Tianjin Lisheng Pharma Gets Nod For Febuxostat Active Pharma Ingredient in China MT
Lisheng Pharma Unit's Drug Passes Regulatory Evaluation MT

Chart Tianjin Lisheng Pharmaceutical Co.,Ltd.

Chart Tianjin Lisheng Pharmaceutical Co.,Ltd.
More charts

Company Profile

Tianjin Lisheng Pharmaceutical Co., Ltd. is a China-based company, principally engaged in the manufacture and distribution of chemical drugs. The Company's major products are tablets, hard capsules, pills, free-dry powder injections, water injections and raw drugs, including drugs for cardio and cerebral vascular systems, anti-infection drugs and hormone drugs, among others. It distributes its products mainly within domestic markets.
Sector
Pharmaceuticals
Calendar
2024-08-22 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

1st Jan change Capi.
TIANJIN LISHENG PHARMACEUTICAL CO.,LTD. Stock Tianjin Lisheng Pharmaceutical Co.,Ltd.
-15.52% 565M
SUN PHARMACEUTICAL INDUSTRIES LTD. Stock Sun Pharmaceutical Industries Ltd.
+21.80% 43.81B
OTSUKA HOLDINGS CO., LTD. Stock Otsuka Holdings Co., Ltd.
+30.40% 23.03B
SANDOZ GROUP AG Stock Sandoz Group AG
+21.32% 15.45B
CIPLA LIMITED Stock Cipla Limited
+19.05% 14.4B
ZYDUS LIFESCIENCES LIMITED Stock Zydus Lifesciences Limited
+58.92% 12.95B
THE MEDICINES COMPANY Stock The Medicines Company
-0.05% 6.79B
ONO PHARMACEUTICAL CO., LTD. Stock Ono Pharmaceutical Co., Ltd.
-11.84% 6.49B
STADA ARZNEIMITTEL Stock STADA Arzneimittel
-8.87% 5.73B
ASPEN PHARMACARE HOLDINGS LIMITED Stock Aspen Pharmacare Holdings Limited
+13.00% 5.49B
Generic Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 002393 Stock
  4. News Tianjin Lisheng Pharmaceutical Co.,Ltd.
  5. Lisheng Pharma Unit's Drug Passes Regulatory Evaluation